TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: VAS score after 8 hours
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence of intraoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with at least one adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients presenting EPS
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving anticholinergic treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Height measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery‐Åsberg Depression Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sedation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in social anxiety measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Convenience of gentamicin compared to oral antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comfort of gentamicin compared to oral antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bacteriological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: global well-being
Endpoint domain: Life impact
Endpoint subdomain: global quality of life
Primary endpoint: Quality of life (QoL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recovery by 72 hours postsurgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to readiness for hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Judgment of benefits from adjuvant chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the number of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: footprint coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 role physical and mental health scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: displacement in SCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lower CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in serum basal PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Toxicity in blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achieved target cholesterol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: satisfaction with pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IOP lowering effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate (4 mm Hg ≤ IOP ≤ 15 mm Hg without bleb failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for further clinical/surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Staphylococcus load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in oral carriage of mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Reduction in periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Incidence of invasive colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: six-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrial fibrillation recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean synkinesis score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moderate-to-severe synkinesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sunnybrook composite score at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of neurocognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: circulating sex hormone binding globulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: rate of PSA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to mobilization after sheath removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge after sheath removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for sheath removal method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery assessment from snakebite envenomation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of analgesic drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nausea/vomiting incidence
Endpoint domain: Adverse events/effects
Primary endpoint: ADCS ADL total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: semantic word fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Balance performance (BBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility performance (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of low molecular weight proteins (LMWPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Irritability and Aggression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders on Clinical Global Impression Rating of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat-free mass estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat mass estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength of adhesive systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of autonomic neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in pain VAS at T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain VAS at T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical component of SF-12 at T2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of ischemic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up INR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sleep-wakefulness state improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral SpO2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Zika IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean enhancement levels within the coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lateral patella laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AT blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin-mediated AT glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seroprotection rates after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Microtensile bond strength (μTBS) to dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Silver nitrate penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nanoleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacodynamic effects measured by pupil parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAI (Clinical Activity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of first subsequent biopsy-proven or presumptive rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tx loss or death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in parenting risk and protective factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost–utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in stroke risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hemoglobin A1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from AF after procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day and night time continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urodynamic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in asthmatic symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in disease-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU stay time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxyhemoglobin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSS (Sleep Scale Score)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: visual analog scale scores at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale scores on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale scores on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for blood sampling to assay STB
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of uveitis recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity stabilization or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for adjunctive therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Major coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants with HIV‐1 RNA <40 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ex vivo CD8+ T cell viral inhibitory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: treatment success rate after one session of SWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff inflation pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost per life year saved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: oral discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Task composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcomes after THA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cannabis-positive urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-positive samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine-positive samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with clinical HSV recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Mean anti‐Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the curve of anti‐Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Defect Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise duration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifestyle exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SWAL-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive breath samples (blood alcohol level ≥ 0.004 g/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bond failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: FPP period longer than 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of male enhancement products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile compared to Viagra®
Endpoint domain: Adverse events/effects
Primary endpoint: LCAI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Twitch half-relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tetanic torques at 10 and 100 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Central motor drive (CMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relaxation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfortability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Antipsychotic-induced weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean severity of palpitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unscheduled medical visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FLI score ≥60 at endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative maximum urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effectiveness of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Equivalence of L-T4 dosage forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nasal NO measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexibility test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extension peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of days without heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival free from target-vessel failure
Endpoint domain: Mortality/survival
Primary endpoint: proportion of nonvirologic failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of subretinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal sensitivity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ETDRS letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of substance use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task performance speed and accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nasal symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of death during the first 60 days
Endpoint domain: Mortality/survival
Primary endpoint: percentage of patients with relapse
Endpoint domain: Mortality/survival
Primary endpoint: Collagen fiber density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in viral counts on hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinically significant weight gain (≥ 7%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TDI focal scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exacerbations and exacerbation days
Endpoint domain: Adverse events/effects
Primary endpoint: Blood loss/transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intraabdominal drainage duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients maintaining pVL <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO oral toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease course duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total mean estimated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: need for additional uterotonic agent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ocular itching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean redness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drop comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: menstrual bleeding recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in total and low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac-related health care cost at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correct identification of symbols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Recession (GR) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mucosal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discomfort and pain on removal of packings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Living with Heart Failure Questionnaire (MLwHFQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective arterial blood volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes